- cafead   Feb 02, 2024 at 12:32: PM
via Already reeling from the controversial termination of its CEO, Allarity Therapeutics has now been told that Novartis is rescinding the rights to a troubled cancer drug after the biotech failed to keep up with its payments.
article source
article source